10-Q: Molina Healthcare Reports Q2 2026 Results Amid Membership Decline

Molina Healthcare's Q2 2026 results show a significant decrease in net income and membership compared to the prior year, driven by market contraction and strategic pricing adjustments.

Summary

• Molina Healthcare reported net income of $60 million ($1.19 per diluted share) for Q2 2026, a substantial decrease from $255 million ($4.75 per diluted share) in Q2 2025.
• Total revenue for Q2 2026 was $10.87 billion, down from $11.43 billion in Q2 2025, primarily due to a 14% decrease in membership.
• Consolidated Medical Care Ratio (MCR) increased to 92.2% in Q2 2026 from 90.4% in Q2 2025, indicating higher medical costs relative to revenue.
• General and administrative (G&A) expense ratio rose to 6.7% from 6.2% year-over-year, attributed to lower premium revenues.
• The company recorded a $93 million impairment charge in Q1 2026 related to the planned exit of its Medicare Advantage Prescription Drug (MAPD) product in 2027.
• Membership decreased to 4.9 million at June 30, 2026, from 5.7 million at June 30, 2025, driven by Medicaid market contraction and strategic product/pricing changes in the Marketplace.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant declines in net income, revenue, and membership, coupled with rising medical costs and a notable impairment charge.

Positives

• The company successfully transitioned Medicare-Medicaid Plan (MMP) members in five states to new integrated dual eligible special needs plans on January 1, 2026.
• Despite a decrease in Marketplace membership, the company expects associated revenue loss to be offset by higher revenue in the Marketplace segment due to strategic pricing.
• The company's Medicare segment MCR for Q2 2026 was favorable to expectations due to lower than expected medical cost trends in new integrated duals products.
• The company has $1.25 billion in available borrowing capacity under its Credit Facility as of June 30, 2026.
• The company's working capital was $5.2 billion at June 30, 2026, an increase from $5.1 billion at December 31, 2025.
• The company's regulated health plan subsidiaries remain well capitalized and exceed regulatory minimum requirements.

Negatives

• Net income for Q2 2026 decreased by 76% to $60 million compared to $255 million in Q2 2025.
• Total revenue decreased by 4.8% to $10.87 billion in Q2 2026 compared to $11.43 billion in Q2 2025.
• Membership declined by 14% to 4.9 million in Q2 2026 compared to 5.7 million in Q2 2025.
• Consolidated Medical Care Ratio (MCR) increased by 180 basis points to 92.2% in Q2 2026, indicating increased medical costs.
• The G&A expense ratio increased to 6.7% in Q2 2026 from 6.2% in Q2 2025.
• The company recorded a $93 million impairment charge on intangible assets in Q1 2026.
• Marketplace premium revenue decreased significantly by $572 million in Q2 2026 compared to Q2 2025 due to reduced membership.
• The Marketplace MCR increased to 88.9% in Q2 2026, higher than expected.

Risks

• Potential reductions in Medicaid funding and changes to federal matching percentages.
• Uncertainty regarding the status or effect of Marketplace subsidies and new program integrity rules.
• Budget pressures on state governments may lead to reduced rates and limited rate increases.
• Evolving Marketplace dynamics including enrollment issues, special enrollment periods, and risk adjustment estimates.
• Cyber-attacks, ransomware attacks, or other privacy or data security incidents.
• The success of scaling operations in new states and satisfying readiness review requirements.
• The failure to comply with financial or other covenants in the Credit Agreement or senior note indentures.
• Increasing competition and consolidation in the Medicaid or general healthcare sector.

Future Outlook

The company expects Medicaid enrollment to decrease in 2026 to 4.5 million members by year-end due to market contraction, with revenue loss offset by higher Marketplace revenue. Medicare enrollment is expected to decrease by approximately 12% in 2026, with a target of 230,000 members by year-end. Marketplace enrollment is expected to decrease to approximately 250,000 members by year-end, with further reductions anticipated for 2027, potentially decreasing Marketplace premiums by $1 billion compared to 2026.

Management Comments

• Membership decreased 14% compared with June 30, 2025, primarily due to general market contraction in Medicaid, the expiration of our Medicaid Virginia contract, and a decrease in Marketplace membership resulting from our product and pricing strategy.
• Premium revenue decreased 6% compared with the second quarter of 2025, mainly reflecting the impact of lower membership, partially offset by rate updates.
• Consolidated medical care ratio (MCR) of 92.2% compared with 90.4% for the second quarter of 2025, as we continue to navigate a challenging medical cost environment.
• General and administrative expense (G&A) ratio of 6.7%, compared with 6.2% for the second quarter of 2025, reflecting the impact of lower premium revenues and continued operating discipline.
• Pre-tax margin of 0.8%.

Industry Context

StockSavvy.ai notes that Molina Healthcare's results reflect broader industry pressures, including a contracting Medicaid market and rising medical costs, which are impacting profitability across managed care organizations. The company's strategic shift away from certain products and markets, while potentially impacting short-term revenue, aims to improve long-term margins.

Comparison to Industry Standards

• Molina Healthcare's consolidated MCR of 92.2% for Q2 2026 is higher than the industry average for managed care organizations, which typically aims for MCRs in the mid-80s to low 90s, indicating a more challenging cost environment for Molina.
• The company's strategic reduction in Marketplace membership and focus on restoring target margins aligns with a trend among some insurers to de-emphasize unprofitable or lower-margin product lines to improve overall profitability.
• The decline in Medicaid membership is consistent with reports of states re-evaluating eligibility post-pandemic, impacting companies heavily reliant on this segment.

Legal Proceedings

• A securities class action lawsuit was filed on October 3, 2025, and consolidated on March 31, 2026, alleging violations of federal securities laws related to disclosures and earnings guidance. A motion to dismiss is scheduled for September 2, 2026.
• A shareholder derivative suit was filed on December 12, 2025, alleging breach of fiduciary duty and violation of securities laws. This action is stayed pending resolution of the securities class action.

Stakeholder Impact

• Shareholders may experience negative impacts due to the significant decrease in net income and earnings per share, and a potential impact on stock price.
• Members may be affected by strategic product and pricing adjustments, particularly in the Marketplace segment, and potential enrollment changes in Medicaid.
• Employees may face uncertainty due to the company's strategic shifts and focus on operational discipline.
• Providers may be impacted by changes in membership and potential shifts in payment dynamics within the managed care landscape.

Next Steps

• The company intends to exit its MAPD product for 2027.
• Further reductions in Marketplace enrollment are planned for 2027.
• The company will continue to focus on dual-eligible members in its Medicare segment.
• The company will contest the securities class action and shareholder derivative suit.
• The company will monitor and adapt to legislative and regulatory developments, including the One Big Beautiful Bill Act and Marketplace Program Integrity and Affordability Rule.

Key Dates

Recommendation

While the current results are concerning, with significant declines in key financial metrics and membership, the company's strategic repositioning, focus on core profitable segments, and available credit facility provide some stability. The outcome of ongoing litigation and the success of the strategic shift in the Marketplace segment will be critical factors for future performance. A 'hold' recommendation reflects a wait-and-see approach pending clearer signs of stabilization and margin improvement.

Keywords

Molina Healthcare, Managed Healthcare, Medicaid, Medicare, Marketplace, Health Insurance, Medical Care Ratio, Premium Revenue